Dark

NVS
Novartis AG
stock NYSE ADR

At Close

Jan 30, 2026 3:59:48 PM EST

148.79USD-0.081%(-0.12)1,147,271

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jan 30, 2026 9:28:30 AM EST

149.51USD+0.403%(+0.60)12,290

After-hours

Jan 30, 2026 4:11:30 PM EST

145.08USD-2.493%(-3.71)611

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

04:51PM EST Amgen Reports In 8K Filing Co Entered Into Amendment No. 3 To Exclusive License & Collaboration Agreement With Novartis Benzinga

Jan 26, 2022

08:00AM EST Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. GlobeNewswire Inc

Jan 18, 2022

04:25AM EST Molecular Partners Finalized License Agreement with Novartis for Ensovibep for COVID-19; Molecular Partners to Receive Milestone Payment of CHF150M, 22% Royalty on Ensovibep Sales in Relevant Territories Benzinga

01:26AM EST Molecular Partners AG (MOLN), a clinical-stage biotech company developing DARPin therapeutics, Tuesday said it has entered into a license agreement with Novartis AG (NVS), under which the Swiss drug major will in-license global rights to ensovibep from Molecular Partners. RTTNews

01:12AM EST Molecular Partners Finalizes License Deal With Novartis For Ensovibep For COVID-19 RTTNews

Jan 14, 2022

08:07AM EST The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake Benzinga

Jan 10, 2022

11:55AM EST New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion PR Newswire

04:49AM EST Molecular Partners and Novartis Report Topline Data from Phase 2 Study for Ensovibep Show DARPin Antiviral Therapeutic Candidate for COVID-19 vs. Placebo Met Primary Endpoint of Viral Load Reduction over Eight Days Benzinga

02:44AM EST Molecular Partners AG (MOLN) and Novartis announced positive data from phase 2 study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19. RTTNews

01:43AM EST Molecular Partners, Novartis Report Positive Topline Data From Phase 2 Study For Ensovibep RTTNews

Jan 6, 2022

08:45AM EST Alnylam, Novartis Enter Research Collaboration To Provide RTTNews

07:35AM EST Alnylam Announces Collaboration With Novartis To Explore Targeted Therapy To Restore Liver Function RTTNews

04:51AM EST Novartis Announced Three-Year Collaboration With Alnylam to Explore Targeted Therapy to Restore Liver Function Benzinga

Jan 4, 2022

01:43AM EST Novartis: U.S. CAFC Upholds Validity Of Gilenya Dosage Regimen Patent RTTNews

Dec 23, 2021

10:03AM EST UK's Medicines And Healthcare Products Regulatory Agency Says Novartis Approves License Extension For Co.'s Targeted Therapy For Advanced Breast Cancer Patients In UK Benzinga

08:21AM EST Novartis' Cosentyx Scores FDA Approval For Arthritis In Children, Adolescents Benzinga

08:20AM EST FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol Benzinga

07:29AM EST The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review Benzinga

Dec 22, 2021

04:09PM EST FDA Reports Approval For Leqvio To Lower Cholesterol Benzinga

07:42AM EST The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda Benzinga

05:51AM EST A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of GDP Report Benzinga

04:55AM EST Novartis Unit Sandoz Submitted Marketing Authorization Application for Proposed Biosimilar Trastuzumab to EMA Benzinga

02:38AM EST Sandoz, a generic and biosimilar medicines company and an arm of Novartis (NVS), said on Wednesday that it has filed a Marketing Authorization Application for the proposed biosimilar trastuzumab, developed by EirGenix, Inc., to the European Medicines Agency or EMA. RTTNews

02:32AM EST Syncona Limited (SYNC.L) said it agreed to sell its portfolio company Gyroscope Therapeutics Holdings plc to Novartis (NVS) for up to $1.5 billion on a cash and debt free basis, with an upfront payment of $800 million and up to $700 million potentially due upon the achievement of certain customary milestones related to clinical development, regulatory approvals and reimbursement. RTTNews

02:07AM EST Syncona: Gyroscope Therapeutics To Be Acquired By Novartis For Up To $1.5 Bln RTTNews

02:02AM EST Sandoz Submits Marketing Authorization Application For Proposed Biosimilar Trastuzumab To EMA RTTNews

Dec 20, 2021

09:12PM EST Novartis AG's (NVS) unit Sandoz announced the submission of its Biologics License Application (BLA) for a proposed biosimilar trastuzumab (150 mg, for intravenous use) developed by EirGenix Inc. to the US Food and Drug Administration. RTTNews

06:32AM EST Novartis Inks Option, Collaboration And License Agreement With BeiGene For Ociperlimab RTTNews

06:16AM EST BeiGene Expands Collaboration With Novartis To Develop And Commercialize BeiGene's TIGIT Inhibitor And Market Five Novartis Oncology Medicines In China Broad Markets Benzinga

04:49AM EST Novartis Announced Top-line Results from PEARL 1 and PEARL 2 Phase III Studies in Chronic Spontaneous Urticaria Met Their Primary Endpoints of Superiority for Ligelizumab vs Placebo at Week 12, But Not vs Omalizumab Benzinga

03:11AM EST Novartis AG (NVS) on Monday announced mixed topline results from its twin phase III trials evaluating Ligelizumab in chronic spontaneous urticaria, dubbed PEARL 1 and PEARL 2. RTTNews

01:58AM EST Novartis Reports Top-line Results From PEARL 1 And PEARL 2 Studies In Chronic Spontaneous Urticaria RTTNews

Dec 17, 2021

04:16PM EST The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More Benzinga

Dec 16, 2021

10:38AM EST Novartis AG (NVS) shares are trading more than 5 percent on Thursday morning after the company announced a share buyback of up to $15 billion by end of 2023. The buyback will be funded through the proceeds from the recent sale of 53.3 million Roche bearer shares. RTTNews

08:20AM EST The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street Benzinga

04:58AM EST Novartis Announced New $15B Share Buyback Benzinga

01:23AM EST Swiss drug maker Novartis (NVS) announced Thursday that it will initiate a share buyback of up to $15 billion to be executed by the end of 2023, highlighting confidence in top line growth and deep pipeline. RTTNews

01:05AM EST Novartis To Initiate Share Buyback Of Up To $15 Bln To Be Executed By End Of 2023 RTTNews

Dec 14, 2021

08:22AM EST The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks Benzinga

01:08AM EST Molecular Partners Collaborates With Novartis To Develop DARPin Platform With Novartis' In Radioligand Therapy RTTNews

Dec 13, 2021

11:44AM EST How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal Benzinga

Dec 12, 2021

12:39PM EST Novartis' (NVS) Scemblix demonstrated sustained response rate in 48-week data from the Phase III ASCEMBL study in patients with chronic myeloid leukemia. RTTNews

Dec 11, 2021

01:43PM EST Novartis' (NVS) Kymriah or tisagenlecleucel demonstrated strong efficacy in high-risk patients with relapsed or refractory follicular lymphoma, as per a subgroup analysis from an about 17-month median follow-up of the pivotal Phase II ELARA study. RTTNews

12:17PM EST Novartis Announced Kymriah Demonstrates Strong Responses in High-risk Patients With Relapsed or Refractory Follicular Lymphoma In Extended Study Follow-up at ASH 2021 Benzinga

Dec 10, 2021

08:19AM EST Novartis: New Data Shows Efficacy Of Piqray In HR+/HER2- RTTNews

08:06AM EST Novartis Data Show Efficacy Of Piqray In HR+/HER2- Metastatic Breast Cancer With PIK3CA Driver Mutation RTTNews

08:05AM EST Novartis Highlights Efficacy Data Of Piqray Presented At 2021 San Antonio Breast Cancer Symposium Benzinga

08:02AM EST Novartis data highlight efficacy of Piqray(r) in HR+/HER2- metastatic breast PR Newswire

Dec 9, 2021

09:52PM EST Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients Benzinga

09:44PM EST Novartis Announced Results from Year Two of Phase III Trial of Beovu in Diabetic Macular Edema Confirm Year One Findings With Overall Favorable Benefit-risk Pprofile Benzinga

09:37PM EST Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings Benzinga

Dec 8, 2021

10:09AM EST Novartis : Kisqali Data Shows OS Benefit Across Genomic And Clinical Subtypes Of Interest In Metastatic Breast Cancer RTTNews

09:32AM EST Novartis Says New Kisqali Data Show Consistent Overall Survival Benefit Across Genomic And Clinical Subtypes Of Interest In HR+/HER2- Metastatic Breast Cancer Benzinga

Dec 6, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 Benzinga

07:11AM EST Novartis CEO Said Working on Pan-coronavirus Oral Treatment; Said Need to Follow Science, Wait for More Rigorous Scientific Assessment on Omicron Variant Benzinga

06:20AM EST Exane BNP Paribas Downgrades Novartis to Neutral Benzinga

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 3, 2021

10:17AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021 Benzinga

08:04AM EST Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. RTTNews

06:49AM EST Bryan Garnier Downgrades Novartis to Neutral Benzinga

Dec 2, 2021

01:32PM EST Novartis Shares Quiet; FDA Says Co's Sandoz Issues Nationwide Recall Of 1 Lot Of Enoxaparin Sodium Injection Benzinga

07:51AM EST The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance Benzinga

05:59AM EST Novartis, on R&D Day Said Novartis Confident of Booking Annual Average Compound Sales Growth of At Least 4% to 2026 Benzinga

02:29AM EST UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop RTTNews

01:21AM EST UCB To Partner With Novartis On Development Of UCB0599 With An Opt-in To Develop UCB7853 RTTNews

Nov 23, 2021

07:17AM EST Novartis May Have Buyer(s) For Its Sandoz Unit - Report Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

Nov 8, 2021

10:24AM EST Novartis Says Treatment With Cosentyx Resulted In 72% Reduced Flare Risk Versus Placebo Benzinga

Nov 5, 2021

10:19AM EDT Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs Benzinga

Nov 4, 2021

01:45PM EDT Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial Benzinga

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

07:34AM EDT Novartis To Offload Its Stake Back To Roche For $20.7B Benzinga

04:58AM EDT Novartis, Roche Agreed on Bilateral Transaction for the Sale of Roche Bearer Shares Held by Novartis for $20.7B Benzinga

03:00AM EDT Swiss drug major Novartis (NVS) has agreed to sell 53.3 million Roche bearer shares to Roche for a total consideration of $20.7 billion. RTTNews

02:32AM EDT Novartis To Sell 53.3 Mln Roche Bearer Shares In A Bilateral Transaction To Roche For $20.7 Bln RTTNews

Nov 2, 2021

06:33PM EDT Novartis Inks $1.3B Protein Degradation Deal With UK's Dunad Benzinga

Nov 1, 2021

04:00AM EDT Swiss drug major Novartis (NVS) announced Monday that the US Food and Drug Administration approved Scemblix (asciminib) for the treatment of chronic myeloid leukemia or CML in two distinct indications. RTTNews

Oct 29, 2021

03:48PM EDT Novartis Shares Spike Higher Amid FDA Approval Of Scemblix With Novel Mechanism Of Action For Treatment Of Chronic Myeloid Leukemia Benzinga

Oct 26, 2021

08:36AM EDT The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children Benzinga

08:36AM EDT Novartis: Q3 Earnings Insights Benzinga

08:30AM EDT The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children Benzinga

07:19AM EDT Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook Benzinga

05:05AM EDT Novartis Q3 EPS $1.71 Beat $1.65 Est; Sales $13.03M Beat $13M Est Benzinga

04:39AM EDT Earnings Scheduled For October 26, 2021 Benzinga

01:20AM EDT Swiss drug major Novartis (NVS) reported Tuesday that its third-quarter net income climbed 43 percent to $2.76 billion from last year's $1.93 billion. Earnings per share were $1.23, up 45 percent from $0.85 a year ago. RTTNews

01:02AM EDT Novartis Q3 EPS $1.23; Core EPS $1.71 RTTNews

Oct 25, 2021

11:08AM EDT A Preview Of Novartis's Earnings Benzinga

05:05AM EDT Novartis Announced Canopy-1 Phase III Study Did Not Meet Primary Endpoints of Overall Survival and Progression-free Survival in Patients With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer Benzinga

Oct 22, 2021

09:54AM EDT Price To Earnings Ratio Insights For Novartis Benzinga

Oct 21, 2021

12:11PM EDT Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines Benzinga

Oct 19, 2021

08:23AM EDT The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio Benzinga

02:58AM EDT Novartis AG (NVS) and Global Heart Hub, a non-profit organization formed to support those affected by cardiovascular disease, on Tuesday, announced the launch of a worldwide network of patient organizations and other stakeholders in the cardiovascular space, dubbed Invisible Nation. RTTNews

01:48AM EDT Global Heart Hub And Novartis Launch Invisible Nation Program RTTNews

Oct 14, 2021

12:00PM EDT This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers Benzinga

Oct 13, 2021

05:14AM EDT Novartis AnnounceD FDA and EMA Filing Acceptances of Beovu for Patients with Diabetic Macular Edema Benzinga

Oct 11, 2021

05:16AM EDT Novartis Pharma AG (NOVN) Monday said its unit Sandoz, has completed its acquisition of GlaxoSmithKline's (GSK) cephalosporin antibiotics business for an undisclosed sum. The deal gives Sandoz rights to three established brands Zinnat, Zinacef, and Fortum in over 100 markets. RTTNews

Oct 7, 2021

05:22AM EDT Novartis Announced it Will Present Broad Range of Portfolio Data at ECTRIMS, Reinforcing Long-standing Commitment to People Living With Multiple Sclerosis Benzinga

Oct 6, 2021

12:30AM EDT Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane Benzinga

Sep 30, 2021

02:00AM EDT Novartis (NVS) said it is making steady progress versus its 2025 target to achieve carbon neutrality in its own operations, with a 28% reduction in carbon emissions (Scope 1 and 2) to date from a 2016 baseline. RTTNews

01:26AM EDT Novartis Commits To Achieve Net Zero Across Its Value Chain By 2040 RTTNews

Sep 29, 2021

02:33PM EDT Novartis and Medicines for Malaria Venture report results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria Benzinga

09:29AM EDT Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis Benzinga

05:13AM EDT Novartis Announced Data Show Achieving Complete Control of Chronic Spontaneous Urticaria Improves Overall Quality of Life, as Reported by Patients Benzinga

Sep 22, 2021

10:35AM EDT Green Hygienics Holdings To Raise $100M Via Green Bond Offering Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

07:07AM EDT Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition Benzinga

05:31AM EDT Novartis Acquired Gene Therapy Company Arctos Medical; Financial Terms Not Disclosed Benzinga

Sep 20, 2021

02:30PM EDT Why Did Deutsche Bank Downgrade This Big Pharma Stock? Benzinga

12:40PM EDT Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients Benzinga

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021 Benzinga

08:28AM EDT Deutsche Bank Downgrades Novartis to Sell Benzinga

Sep 19, 2021

09:51AM EDT Novartis Announced New Kisqali Data Showing Median Overall Survival Benefit of 63.9 Months in HR+/HER2- Advanced Breast Cancer Benzinga

09:46AM EDT The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight Benzinga

07:44AM EDT Novartis Presents Kisqali Data Showing Longest Median Overall Survival Ever Reported In HR+/HER2- Advanced Breast Cancer RTTNews

07:35AM EDT Novartis presents new Kisqali(r) data showing longest median overall survival PR Newswire

Sep 17, 2021

08:18AM EDT Novartis (NVS) announced findings from a real-world study, which evaluated the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum or PROS who received treatment daily for at least 24 weeks. RTTNews

07:46AM EDT Novartis Reports Findings From Real-world Study Evaluating Safety And Efficacy Of Alpelisib RTTNews

07:38AM EDT Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS) Benzinga

06:51AM EDT Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life Benzinga

Sep 16, 2021

10:17PM EDT Novartis (NVS) announced positive health-related quality of life or HRQoL data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer or mCRPC versus standard of care alone. RTTNews

Sep 13, 2021

05:10AM EDT BeiGene Announced FDA Acceptance of Biologics License Application for Tislelizumab, Filed in Collaboration with Novartis, in Esophageal Squamous Cell Carcinoma Benzinga

01:48AM EDT BeiGene Ltd. (BGNE) said Monday that the U.S. Food and Drug Administration accepted for review a Biologics License Application or BLA for its anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma or ESCC after prior systemic therapy. RTTNews

01:39AM EDT BeiGene Announces FDA Acceptance For Tislelizumab BLA In Esophageal Squamous Cell Carcinoma RTTNews

Sep 10, 2021

07:36PM EDT ADHD Drug Developer Cingulate Plans NASDAQ Debut Benzinga

Sep 8, 2021

08:53AM EDT Sandoz, a Novartis division (NVS), said that it has reached a commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions Ltd., for treatment of multiple types of cancers. RTTNews

08:16AM EDT Sandoz Enters Commercialization Agreement With Bio-Thera Solutions For Biosimilar Bevacizumab RTTNews

Sep 3, 2021

07:10AM EDT Novartis Stops Iscalimab Trial In Kidney Transplant Patients Benzinga

05:45AM EDT Novartis Presents New Findings at ERS Congress Reinforcing Efficacy of Enerzair Breezhaler, Highlighting Its Digital Companion, Showcasing Commitment to Low Carbon Footprint Asthma Solutions Benzinga

Sep 2, 2021

10:02AM EDT Price Over Earnings Overview: Novartis Benzinga

05:28AM EDT Novartis Received FDA Fast Track Designation for LNA043 In Osteoarthritis of the Knee Benzinga

Sep 1, 2021

06:25AM EDT Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio Benzinga

Aug 31, 2021

10:52PM EDT Novartis (NVS) and United Kingdom's National Health Service reached an agreement that will enable broad access to the Swiss drug giant's anti-cholesterol drug Leqvio or inclisiran for hundreds of thousands of high-risk cardiovascular patients. RTTNews

Aug 30, 2021

09:08AM EDT Novartis Says Sabatolimab Receives Orphan Drug Designation From European Commission For Myelodysplastic Syndromes Benzinga

04:54AM EDT Novartis Announced Data Supporting Upcoming Regulatory Filings for Tislelizumab in People With Squamous and Non-squamous Non-small Cell Lung Cancer, and for Alpelisib in People With PIK3CA-related Overgrowth Spectrum at ESMO Benzinga

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 25, 2021

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

07:27AM EDT Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia Benzinga

Aug 24, 2021

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

07:50AM EDT Novartis's Kymriah Flunks In Late-Stage NHL Study Benzinga

05:05AM EDT Novartis Announced Phase III BELINDA Study Did Not Meet Primary Endpoint of Event-free Survival for Patients With Aggressive B-cell Non-hodgkin Lymphoma Who Had Primary Refractory Disease or Who Relapsed Within 12 Months of First-line Treatment Benzinga

03:20AM EDT Swiss drug major Novartis (NVS) announced Tuesday that its Phase III BELINDA study investigating Kymriah (tisagenlecleucel) did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma or NHL. RTTNews

Aug 17, 2021

06:17AM EDT Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies Benzinga

05:17AM EDT Novartis Announced Results From Phase III Trials of Beovu in Diabetic Macular Edema Reaffirmed Visual Acuity Gains and Fluid Reduction Findings as Well as Safety Profile From Year One Benzinga

Aug 12, 2021

07:26AM EDT Global pharmaceutical company Cipla Limited has received final FDA approval for its Abbreviated New Drug Application for Difluprednate Ophthalmic Emulsion 0.05%. It is AB-rated generic therapeutic equivalent version of Novartis Pharmaceuticals Corporation's Durezol. The company said the product will be available for shipping soon. RTTNews

Aug 11, 2021

02:06PM EDT WHO-Led Study To Test Three Anti-Inflammatory Drugs For COVID-19 Benzinga

07:55AM EDT WHO Says Solidarity Clinical Trial Enters New Phase With Three New Candidate Drugs For Treating COVID-19; Artesunate, Imatinib And Infliximab Were Selected By An Independent Expert Panel For Potential In Reducing The Risk Of Death In Hospitalized Patients Benzinga

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

01:42AM EDT Novartis (NVS) said the U.S. Food and Drug Administration has concluded that OAV-101 intrathecal or IT clinical trials for spinal muscular atrophy or SMA patients may proceed, thereby lifting the partial clinical trial hold initiated in October 2019. RTTNews

01:29AM EDT Novartis: FDA Determine That OAV-101 Intrathecal Clinical Trials For SMA Patients May Proceed RTTNews

Aug 2, 2021

12:33PM EDT Cannabis Movers & Shakers: BioHarvest Sciences, Green Hygienics, Realm of Caring, Media Central Corp, Al Harrington's Viola Benzinga

09:33AM EDT Ionis Pharmaceuticals Says Lp HORIZON Achieves 50% Enrollment In Trial To Assess Safety, Efficacy Of Pelacarsen In Reducing Recurrent Cardiovascular Events Benzinga

09:32AM EDT Lp HORIZON Achieves 50% Enrollment In Trial To Assess Efficacy Of Pelacarsen In Reducing Recurrent Cardiovascular Events RTTNews

09:31AM EDT Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and PR Newswire

Jul 30, 2021

04:15PM EDT Adicet Bio In 8K Filing Says Delivered Written Notice To Novartis To Terminate Certain License Agreement, Effective On Or Before Oct. 1, 2021; Says Co. Is Not Subject To Any Termination Penalties Related To Termination Of License Agreement Benzinga

04:13PM EDT Adicet Bio Says Delivered Written Notice To Novartis To Terminate Certain License Agreement, Effective On Or Before Oct. 1, 2021; Says Co. Is Not Subject To Any Termination Penalties Related To Termination Of License Agreement Benzinga

03:49PM EDT Rani Therapeutics Debuts On The Nasdaq: What You Should Know About The Biopharma Benzinga

Jul 28, 2021

11:33AM EDT Why XOMA Stock Is Trading Higher Wednesday? Benzinga

Jul 27, 2021

02:21PM EDT Novartis' TGF Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 21, 2021

10:36AM EDT Recap: Novartis Q2 Earnings Benzinga

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

06:43AM EDT Earnings Scheduled For July 21, 2021 Benzinga

06:04AM EDT A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings Benzinga

05:09AM EDT Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance Benzinga

01:24AM EDT Swiss drug major Novartis (NVS) reported Wednesday that its second-quarter net income climbed 55 percent to $2.90 billion from last year's $1.87 billion, driven by momentum of key growth brands. RTTNews

01:03AM EDT Novartis Q2 EPS $1.29; Core EPS $1.66 RTTNews

Jul 20, 2021

10:38AM EDT Earnings Outlook For Novartis Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

07:12AM EDT Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients Benzinga

Jul 13, 2021

06:56AM EDT Cowen Initiates Coverage On Molecular Partners With Price Target Of $50 Benzinga

Jul 12, 2021

06:12AM EDT Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159 Benzinga

Jul 8, 2021

09:05AM EDT Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant Benzinga

Jul 6, 2021

07:37AM EDT Kura Oncology Announces Clinical Collaboration With Novartis To Evaluate Tipifarnib In Combination With Alpelisib RTTNews

05:18AM EDT Novartis Announced Complete Response Resubmission to FDA for the Inclisiran NDA Benzinga

Jul 1, 2021

03:08PM EDT Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters Benzinga

Jun 30, 2021

03:37PM EDT Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut Benzinga

Jun 29, 2021

03:17PM EDT Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact Benzinga

Jun 28, 2021

01:42AM EDT Novartis (NVS) said that it has appointed Rob Kowalski, Global Head Regulatory Affairs and US Head of Drug Development, as Chief People & Organization Officer. He become a member of the Executive Committee of Novartis, effective September 1, 2021. RTTNews

01:23AM EDT Novartis Appoints Rob Kowalski As Chief People & Organization Officer RTTNews

Jun 21, 2021

07:24AM EDT Novartis Touts More Positive Zolgensma Data In Spinal Muscular Atrophy Patients Benzinga

Jun 18, 2021

12:34PM EDT Novartis Says New Zolgensma Demonstrate Age-Appropriate Development When Used Presymptomatically And Rapid, Clinically Meaningful Efficacy In Symptomatic Children, Even Those With Severe SMA At Baseline Benzinga

Jun 17, 2021

04:22PM EDT Intellia Therapeutics On Jun. 14 Entered Amendment To Collaborative Research Agreement With Novartis; Amendment Amends Novartis' Rights With Respect To CAR-T Therapeutic Targets Under Agreement Benzinga

Jun 11, 2021

05:13AM EDT Novartis Announced Investigational Oral Therapy Iptacopan SSubstantially Reduced Both Intra- and Extravascular Hemolysis When Given as Monotherapy in a Phase Ii Study of Anti-C5 Nave Paroxysmal Nocturnal Hemoglobinuria Patients Benzinga

Jun 7, 2021

09:38AM EDT Novartis's Iptacopan Aces Mid-Stage Kidney Disease Trial Benzinga

06:32AM EDT Novartis Announces New Interim Analysis Phase II Data For Iptacopan In Rare Kidney Disease C3 Glomerulopathy Benzinga

Jun 6, 2021

10:23PM EDT Novartis (NVS) said that an investigational iptacopan or LNP023- an oral, targeted factor B inhibitor- met Phase II study primary endpoint in rare kidney disease IgA nephropathy or IgAN. RTTNews

Jun 4, 2021

03:10PM EDT Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival Benzinga

10:38AM EDT Novartis Announces Tabrecta First Published Overall Survival &updated Overall Response Data In METex14 Metastatic NSCLC RTTNews

09:46AM EDT Novartis AG (NVS) announced Friday results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy. RTTNews

09:39AM EDT The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact Benzinga

09:11AM EDT Novartis Says Tislelizumab Met Primary Endpoint Of Overall Survival In Pivotal Phase III Trial RTTNews

Jun 3, 2021

05:09PM EDT Novartis Says Co Reports Clinically Relevant Improvement In Median Overall Survival Data In Final Analysis Of Pivotal NETTER-1 Study With Targeted Radioligand Therapy Lutathera Benzinga

03:21PM EDT Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months Benzinga

12:09PM EDT Novartis Says Its Candidate For Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Showed Improvements In Overall Survival Benzinga

Jun 2, 2021

03:59PM EDT Novartis Reports Strong Response Rates In Kymriah Drug RTTNews

10:00AM EDT Novartis Kymriah Trial Shows Strong Response Rates And Safety Profile In R/r Follicular Lymphoma RTTNews

09:56AM EDT Novartis AG (NVS) announced Wednesday updated median overall survival (OS) results for Kisqali (ribociclib) in combination with fulvestrant in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer. RTTNews

09:09AM EDT Novartis Announces Updated Median Overall Survival Results For Kisqali Plus Fulvestrant RTTNews

08:20AM EDT The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements Benzinga

07:05AM EDT Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis Benzinga

07:02AM EDT Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients Benzinga

01:53AM EDT Novartis (NVS) said that phase III JUNIPERA study met its primary endpoint, with Cosentyx or secukinumab showing significantly longer time to flare (longer time to worsening of symptoms) compared to placebo in pediatric patients with two subtypes of juvenile idiopathic arthritis or JIA. RTTNews

01:26AM EDT Novartis: Phase III JUNIPERA Study Met Its Primary Endpoint RTTNews

Jun 1, 2021

09:56PM EDT The U.S. Food and Drug Administration has approved Novartis' (NVS) Cosentyx or secukinumab for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. RTTNews

04:32PM EDT Novartis' COSENTYX Receives FDA Approval For Treatment Of Children And Adolescents With Moderate To Severe Plaque Psoriasis Benzinga

08:15AM EDT Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety Benzinga

May 28, 2021

04:45PM EDT Novartis Announces Beovu Met Merlin's Primary Endpoint Of Non-inferiority In Change In Best Corrected Visual Acuity From Baseline Benzinga

May 27, 2021

12:36PM EDT Artificial Intelligence Doctor App Ada Health Closes $90M Funding Led By Bayer, Samsung Benzinga

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

08:19AM EDT Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment Benzinga

01:53AM EDT Novartis (NVS) and Molecular Partners said that it will start the clinical trial EMPATHY, a Phase II and III study, to explore the use of its DARPin therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. RTTNews

01:25AM EDT Novartis And Molecular Partners Announce Start Of EMPATHY Clinical Trial For Ensovibep For COVID-19 RTTNews

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 24, 2021

04:08PM EDT Novartis' Sandoz Reports Generic Treporostinil Injection Now Available For Subcutaneous Route Of Administration To Treat Pulmonary Arterial Hypertension Patients In US Benzinga

May 18, 2021

05:18AM EDT Novartis to Close Sandoz Generics Site in Spain to Reduce Costs Benzinga

May 17, 2021

04:37PM EDT Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report Benzinga

12:41PM EDT Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks Benzinga

11:18AM EDT Sandoz, a Novartis (NVS) unit, said Monday that the US Supreme Court has denied its petition to review the Federal Circuit's July 2020 decision concerning the Sandoz biosimilar Erelzi or etanercept-szzs for reference medicine Enbrel or etanercept. The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen's patents. RTTNews

09:36AM EDT U.S. Supreme Court Declines To Hear Novartis AG's Appeal In Patent Dispute Over Amgen's Enbrel Arthritis Drug Benzinga

May 12, 2021

09:44PM EDT 15 European Dividend Aristocrats To Diversify Your Portfolio Benzinga

02:42PM EDT Cannabis Industry Salary Report: Increased Demand For Top Talent As Salaries Continue To Surge Benzinga

May 3, 2021

07:35AM EDT Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study Benzinga

01:18AM EDT Sandoz Confirms Late-stage Clinical Development Plans For Proposed Biosimilar Aflibercept RTTNews

May 1, 2021

10:53AM EDT Novartis AG (NVS) said that phase III Beovu data showed potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept. RTTNews

Apr 30, 2021

10:19AM EDT Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla Benzinga

09:21AM EDT Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress Benzinga

12:19AM EDT Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla Benzinga

Apr 27, 2021

02:34PM EDT Eli Lilly Abandons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications Benzinga

07:46AM EDT Novartis Q1 Earnings Take A Hit Amid COVID-19 Impact Benzinga

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

04:05AM EDT Earnings Scheduled For April 27, 2021 Benzinga

01:24AM EDT Novartis AG (NVS) reported that its first-quarter net income declined 5% or 7% at constant currencies to $2.1 billion from the previous year, mainly due to lower operating income. Earnings per share was $0.91 down from $0.96 in prior year. RTTNews

Apr 23, 2021

07:32AM EDT Knight Therapeutics to Acquire Regional Rights to Exelon In Canada And Latin America And Exclusive License To Use IP And Exelon From Novartis Within Territory; Co. To Pay $168M At Closing And Additoinal Milestone Of Up To $12M Benzinga

Apr 21, 2021

11:15AM EDT BioNTech CFO Sees Scope For Additional Production Sites To Meet Demand For COVID-19 Shots: Reuters Benzinga

Apr 13, 2021

01:42AM EDT Roche (RHHBY) said Tuesday that it has received an approval from the U.S. Food and Drug Administration for its supplemental Biologics License Application of Xolair or omalizumab prefilled syringe for self-injection across all approved U.S. indications. RTTNews

Apr 12, 2021

01:21PM EDT Novartis Receives FDA Approval Of Xolair Self-Injection With Prefilled Syringe Across All Indicators For Appropriate Patients Benzinga

Apr 7, 2021

08:08AM EDT Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy Benzinga

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

07:08AM EDT Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio Benzinga

02:35AM EDT Novartis Collaborates With Artios To Use Three DDR Targets RTTNews

02:23AM EDT Artios Pharma Announces Global Research Collaboration With Novartis RTTNews

12:21AM EDT Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators Benzinga

Mar 30, 2021

12:51PM EDT Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal Benzinga

12:10PM EDT Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know Benzinga

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:06AM EDT Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis Benzinga

02:20AM EDT Denmark-based Genmab A/S (GMXAY.PK) announced Tuesday that the European Commission has granted Novartis (NVS) marketing authorization to use Kesimpta (ofatumumab) to treat relapsing forms of multiple sclerosis or RMS in adults with active disease defined by clinical or imaging features. RTTNews

01:52AM EDT Novartis Gets European Approval For Kesimpta For Relapsing Forms Of Multiple Sclerosis In Adults RTTNews

01:48AM EDT Novartis Expands Targeted Radioligand Therapy Pipeline RTTNews

Mar 29, 2021

11:16AM EDT Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know Benzinga

document.getElementById("KV6R7L").onerror = function(){this.style.display='none';}; .dark-mode .pKKcHz{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .pKKcHz{ color: #333333; background-color: white; border: 2px solid #333333; }NVSNovartis AGstock NYSE ADR

NVS
Novartis AG
stock NYSE ADR